New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 20, 2019 - The FDA approved US WorldMeds’ Myobloc (rimabotulinumtoxinB), for the treatment of chronic sialorrhea in adults.
Download PDF
Return to publications
